Literature DB >> 29800416

Urocortin 2: will a drug targeting both the vasculature and the right ventricle be the future of pulmonary hypertension therapy?

Kurt R Stenmark1, Brian B Graham1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29800416      PMCID： PMC6279057          DOI： 10.1093/cvr/cvy117

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  17 in total

Review 1.  Epidemiology and treatment of pulmonary arterial hypertension.

Authors:  Edmund M T Lau; Eleni Giannoulatou; David S Celermajer; Marc Humbert
Journal:  Nat Rev Cardiol       Date:  2017-06-08       Impact factor: 32.419

Review 2.  Evolution and phylogeny of the corticotropin-releasing factor (CRF) family of peptides: expansion and specialization in the vertebrates.

Authors:  David A Lovejoy; Louise de Lannoy
Journal:  J Chem Neuroanat       Date:  2013-09-25       Impact factor: 3.052

3.  Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.

Authors:  Mihai Gheorghiade; Stephen J Greene; Piotr Ponikowski; Aldo P Maggioni; Jerzy Korewicki; Cezar Macarie; Marco Metra; Jacek Grzybowski; Serban-Ion Bubenek-Turconi; Waldemar Radziszewski; Allan Olson; Orlando F Bueno; Atalanta Ghosh; Lawrence I Deckelbaum; Lilian Y Li; Ayan R Patel; Andreas Koester; Marvin A Konstam
Journal:  Eur J Heart Fail       Date:  2013-03-06       Impact factor: 15.534

4.  Urocortin increased endothelial ICAM1 by cPLA2-dependent NF-κB and PKA pathways in HUVECs.

Authors:  Rong Wan; Yunxin Liu; Li Li; Chao Zhu; Lai Jin; Shengnan Li
Journal:  J Mol Endocrinol       Date:  2013-12-20       Impact factor: 5.098

Review 5.  The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology.

Authors:  Edward W Hillhouse; Dimitris K Grammatopoulos
Journal:  Endocr Rev       Date:  2006-02-16       Impact factor: 19.871

6.  Urocortin 2 infusion in human heart failure.

Authors:  Mark E Davis; Christopher J Pemberton; Timothy G Yandle; Steve F Fisher; John G Lainchbury; Christopher M Frampton; Miriam T Rademaker; Mark Richards
Journal:  Eur Heart J       Date:  2007-08-25       Impact factor: 29.983

7.  Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.

Authors:  Rui Adão; Pedro Mendes-Ferreira; Diana Santos-Ribeiro; Carolina Maia-Rocha; Luís D Pimentel; Cláudia Monteiro-Pinto; Eamon P Mulvaney; Helen M Reid; B Therese Kinsella; François Potus; Sandra Breuils-Bonnet; Miriam T Rademaker; Steeve Provencher; Sébastien Bonnet; Adelino F Leite-Moreira; Carmen Brás-Silva
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

8.  Distribution of urocortins and corticotropin-releasing factor receptors in the cardiovascular system.

Authors:  Kazuhiro Takahashi
Journal:  Int J Endocrinol       Date:  2012-05-17       Impact factor: 3.257

9.  Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo.

Authors:  Akinori Hasegawa; Kengo Sato; Remina Shirai; Rena Watanabe; Keigo Yamamoto; Kaho Watanabe; Kyoko Nohtomi; Tsutomu Hirano; Takuya Watanabe
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

Review 10.  Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future.

Authors:  Mark P Lythgoe; Christopher J Rhodes; Pavandeep Ghataorhe; Mark Attard; John Wharton; Martin R Wilkins
Journal:  Pharmacol Ther       Date:  2016-04-29       Impact factor: 12.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.